AbstrAct
L eptin is a metabolic and neuroendocrine hormone produced and released mainly by adipocytes (1) . Several systemic effects are attributed to leptin such as body mass control, lipid and glucose metabolism, thermogenesis, angiogenesis, immunity, reproductive, endocrine and cardiovascular functions, among other (2) . Increased leptin is associated with adiposity and it is expected to reduce food intake and increase energy expenditure by binding to leptin receptors that further activate the hypothalamic melanocortin pathway and control body fat stores (3) .
Several studies have suggested that variants in the leptin gene (LEP) may be important in the pathophysiology of human obesity (4) (5) (6) . A common single nucleotide polymorphism (SNP) within the 5' promoter region (-2548G>A) of the LEP has been associated with variations in plasma leptin and body mass index (BMI) in obese individuals (6) (7) (8) (9) .
Microsatellite markers such as the highly variable tetranucleotide repeat (TTTC) n located in the 3'-flanking region of the LEP (3'HVR) has also been associated with obesity-related traits and leptin plasma levels (6, 10, 11) . However, the relation of this variant with other polymorphisms in the LEP gene on metabolic and obesity-related characteristics remains to be investigated.
In this study, the relationship between LEP 3´HVR and -2548G>A variants and obesity-related phenotype and metabolic biomarkers was investigated in a sample of the Brazilian population.
sUbJEcts AnD MEtHODs study population
Two-hundred-ten unrelated individuals were randomly selected from Instituto Dante Pazzanese de Cardiologia (IDPC), Sao Paulo, Brazil. These individuals were declared to have European ancestry (non-African) by physical examination, however lack of relationship between color and genomic ancestry have been found in Brazilian samples (12) . Sample size was estimated as 267 individuals considering 50% the frequency of LEP alleles related with obesity (95% confidence level, 5% confidence interval, and over 20,000 population size). Individuals with thyroid, liver or kidney diseases, evaluated by clinical and laboratory analyses, and pregnant women were not included in this sample.
Anthropometric measurements, such as BMI, waist circumference (WC) and waist-to-hip ratio (WHR) were taken from each participant. Individuals with BMI ≥ 30 kg/m² were classified as obese and those with systolic/diastolic blood pressure over 140/90 mmHg or under lowering-pressure therapy were considered hypertensive. Individuals with fasting glycemia > 100 mg/dL were considered hyperglycemic. Cigarette smoking was considered when individuals smoked 3 or more cigarettes/day. Sedentary life style was considered when individuals practiced less than a 30 min walk 3 times a week. The presence of coronary artery disease (CAD) was investigated by coronary angiography. The study protocol was approved by the Local Ethics Committees (Institute of Cardiology Dante Pazzanese and School of Pharmaceutical Sciences, University of Sao Paulo).
biomarker analysis
Blood samples were collected from each participant after a 12-hour fasting for serum chemistry tests. Glucose, triglycerides, and total cholesterol and high-density lipoprotein (HDL) cholesterol were measured by enzymatic-colorimetric assays using a Roche-Hitachi 912 automated analyzer (Hitachi, Nakakojo, Japan). Low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol were calculated. Apolipoproteins AI (apoAI) and B (apoB) were determined in serum by nephelometry. Plasma leptin was determined by an ELISA method (Alexis Biochemical/Vendor BioAgency, Sao Paulo, Brazil). The atherogenic index of plasma (AIP) calculated as log (triglycerides/ HDL cholesterol), and ApoB/ApoAI ratio were used for evaluation of thecardiovascular risk.
DnA genotyping
Genomic DNA was extracted from 1 mL EDTA-anticoagulated whole blood by a salting-out method (13) . LEP -2548G>A and 3´HVR polymorphisms were genotyped by polymerase chain reaction (PCR) and fragment analysis as previously described (8, 11) . The accuracy of the genotyping was evaluated by performing duplicate analysis of 20% samples randomly selected. Moreover, heterozygous LEP -2458G>A and 3´HVR samples were included as genotype controls in each run.
statistical analysis
LEP 3´HVR alleles were grouped in class I (short) and class II (long) as previously described (11 Anthropometric, demographic and biochemical data of the studied group are shown in table 1. Four women refused to inform their ages. One woman and one man did not have their waist and hip measured. Obese individuals (BMI > 30 kg/m 2 ) had higher means of age and anthropometric data (BMI, WC and WHR) as well as higher frequencies of hypertension, hyperglycemia, cigarette smoking, sedentary life style and CAD when compared with the non-obese group (p < 0.05). Plasma leptin was also higher in obese than in the non-obese group (p < 0.05).
LEP 3´HVR class I/I and I/II genotypes were more frequent in obese (I/I: 24%, I/II: 56%) than in non-obese individuals (I/I: 21%, I/II: 44%, p = 0.043) ( Table 1) . For -2548G>A polymorphism, the frequency of the GG genotype in obese (41%) was similar to that found in non-obese (28%) (p = 0.090) individuals. Both LEP 3´HVR and -2548G>A variants were under HWE in this sample (Table 1) . A linkage disequilibrium was found between these polymorphisms (D' index = 0.7113). We found nine LEP combined genotypes that were grouped as: I/G (I/IGG + I/IGA+ I/ IIGG); II/A (I/IIAA + II/IIAA + II/IIGA); and others (I/IAA + I/IIGA + II/IIGG). Obese individuals had higher frequencies of I/G combined genotypes (45%) than non-obese subjects (27%, p = 0.018).
Results from univariate logistic regression analysis are shown in more risk for obesity than the -2548AA genotype carriers (p < 0.05). In addition, the risk for obesity was 4 times higher in I/G carriers (OR: 3.97, 95% CI: 1.30 -5.55) than in those carrying II/A (p = 0.012).
Multivariate logistic regression analysis using stepwise criteria for selection of the genetic variables related with obesity was also tested. After adjustment for covariates (age, hypertension, hyperglycemia, cigarette smoking, sedentary life style and CAD), only the LEP -2548GG genotype was associated with an increased risk for obesity (OR: 9.43, 95% CI: 1.84 -48.31; p = 0.007) (data not shown).
The relationship between LEP variants and anthropometric and blood chemistry variables were also investigated in this study (Table 3) . Individuals carrying I/G genotypes had higher serum triglycerides when compared to the II/A carriers (p < 0.05). AIP values were also higher in I/G carriers than in those carrying other genotypes (p < 0.05). We investigated whether the relationship between LEP variants and these variables were influenced by gender, considering that leptin and obesity-related traits (BMI, WC, WHR) were higher in women than in men (p < 0.05) (data not shown). I/G genotypes were associated with higher WC, BMI and leptin values in women but not in men (Figure 1) .
Univariate linear regression analysis showed that the variations in log-transformed values of the BMI were partially explained by LEP 3´HVR class I/II genotype (1.80%, p = 0.046) and -2548GG genotype (2.20%, p = 0.009), as indicated by the determinant coefficient (R 2 ) (Table 4) . Moreover, only 2% of variation in log-transformed plasma leptin is explained by LEP -2548GG genotype (p = 0.031). Regression coefficients (estimates) indicate that the carriers of the 3´HVR class I/II genotype had log-transformed BMI 0.03 more than the non-carriers. Moreover, log plasma leptin was 0.11 higher in 3´HVR class I/II genotype and 0.20 higher in -2548GG genotype in comparison with those carrying other genotypes (Table 4) . We also investigated whether the LEP variants were associated with hypertension, hyperglycemia, dyslipidemia and CAD but no relationship was found between these clinical conditions and LEP variants in this sample (data not shown).
DIscUssIOn
The LEP variants evaluated in this sample were associated with obesity. Individuals carrying the -2548GG genotype have higher risk for increased BMI than carriers of the -2548GA+AA genotypes. Moreover, the -2548GG genotype carriers have 8 times more risk for obesity than the non-carriers suggesting that LEP -2458G>A polymorphism maybe a good predictor for obesity.
The association between LEP -2548G>A polymorphism and increased BMI was also found in overweight Europeans and Taiwanese Aborigines with extreme obesity (15, 16) . We have also found a relationship between the -2548G>A variant and increased plasma leptin and BMI in Brazilian women (8) . It is important to mention that the relationship between -2548GG genotype and obesity was found in recessive and codominant models, but not in the dominant model (16) .
In addition, common variants located in the 5´region of the LEP, including -2548G>A, were associated with increased BMI in men (17) . The presence of the GG genotype was also associated with increase in BMI and weight gain in persons treated with olanzapine (18) (19) (20) . However, no association was found between this polymorphism and obesity in a population-based case control study in Spain (21) .
In this study, LEP -2458GG genotype was also shown to be a predictor for increased plasma leptin. This result confirms the findings from other investigations that showed an association between -2458AA (-/-) genotype and lower leptin levels in Caucasian obese girls and diabetic individuals from China (22, 23) . Conversely, as commented previously, -2458AA genotype was associated with increased plasma leptin in obese individuals (15) . Moreover, carriers of this genotype had lesser decrease in circulating leptin after gastric banding surgery (24) . The results from these studies are suggestive that the relationship between LEP -2548G>A and obesity-related phenotypes may be influenced by sample characteristics such as gender, sample size, population and other.
The variant -2548G>A has been implicated in the regulation of LEP mRNA expression and consequently leptin plasma levels (25) . Gong and cols. (26) have described two repetitive sequences MER11 and Alu located at the LEP promoter (-2514 to 1545) that may regulate LEP expression (26) . In addition, the 3-kb 5´-flanking region contains several putative binding sites for known transcription factors, including CREB, GRE, Sp1, LP1, C/EBP and TATA motifs (26, 27) . A Sp1 functional placental enhancer was found within the MER11 repetitive element suggesting that expression of leptin is the result of insertion of this element (28) . Recently, Moreno-Aliaga and cols. (29) reported that the Sp1 binding site has a key role in the transcriptional activation of the LEP promoter by insulin-mediated glucose metabolism (29) . Whether the -2548G>A variant located close to a Sp1 binding site (-2539) also modulates the transcription of the LEP remains to be investigated.
The role of leptin in body fat control is mediated by leptin receptors (LEPR) in specific hypothalamic centers that stimulate the production of anorectic peptides and inhibit the orexigenic molecules (30) . LEPR gene (LEPR) polymorphisms have also been associated with increased BMI and other obesity-related characteristics in several populations (4, (31) (32) (33) . The combination of LEP -2548G>A and LEPR Q223R variants was related Arq Bras Endocrinol Metab. 2010;54/3 LEP variants, obesity and metabolic biomarkers to a 58% increase in obesity risk in another sample of our population (34) . Therefore, the relationship between LEP -2548G>A and increased BMI found in this study may be due to its linkage to Q223R or other LEPR polymorphisms.
The LEP 3´HVR is a (TTTC) n tetranucleotide repeat located at the 3' end of the LEP that has been associated with increased risk for obesity and high plasma leptin levels as well (10) (11) . These effects may be due to the linkage of the 3'HVR with -2548G>A variant.
The presence of the LEP I/G genotypes was associated with an increased risk for obesity-related phenotype (BMI and WC) and the biomarker of plasma leptin. The influence of I/G variant was further demonstrated to be related to gender, even though this variable did not affect the distribution of the LEP I/G genotypes. Accordingly, it has been shown that the association between a LEP variant (A19G) and risk for obesity was restricted to females from the Atherosclerosis Risk in Communities (ARIC) Study (35) .
Differences in plasma glucose were not related to LEP I/G genotypes, confirming the lack of association between these variants and hyperglycemia. This result suggests that LEP variants may not be implicated in glucose homeostasis. Accordingly, insulin responses to glucose and insulin sensitivity were similar among Japanese carriers of LEP 3´HVR genotypes (36) . Serum triglycerides and AIP values were found to be higher in LEP I/G carriers suggesting a possible role of LEP combined genotypes in lipid metabolism and cardiovascular risk. However, association analyses did not show relationship of the LEP variants with dyslipidemia and CAD evaluated by coronary angiography. Therefore, further investigations are necessary to evaluate these data in larger populations.
The lack of association between hypertension or cardiovascular disease and LEP 3´HVR has been also shown in other populations (37) (38) (39) . Therefore, the association between obesity and hypertension and other risk factors for CAD previously found in our sample (8) seems to be independent of the LEP I/G genotypes.
It is noteworthy that the results from this study may be influenced by the limited sample size, which reduced the power of the statistical tests. Therefore studies with larger samples from the Brazilian population are necessary to confirm our findings.
In conclusion, -2548G>A and 3´HVR variants of the LEP gene are in linkage disequilibrium, and I/G combined genotypes are associated with obesity-re lated biomarkers and phenotype and it is likely that they contribute to the regulation of circulating leptin and triglycerides in a gender-dependent manner.
